Multiplexed testing for EGFR and ALK gene rearrangements may be cost-effective for NSCLC treatment

Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.



from The Medical News http://ift.tt/1JWuedj